Boji Pharma secures patent for tranexamic acid formulation

Guangzhou Boji Medical & Biotechnological (SZSE:300404), also known as Boji Pharma, announced on February 6, 2025, that it has been granted a patent by the China National Intellectual Property Administration for a new tranexamic acid drug composition and its manufacturing process. Patent number ZL 2023 1 1771565.5, applied for on December 21, 2023, and granted on January 28, 2025, covers a formulation that addresses issues with existing tranexamic acid medications, such as rapid release and gastrointestinal irritation. The new formulation offers improved drug delivery, reduced side effects, easier manufacturing, and cost-effectiveness. While the company doesn't expect a significant immediate impact on its financial performance, the patent strengthens Boji Pharma's intellectual property portfolio and supports its ongoing innovation strategy.